Johnson & Johnson (JNJ)vsKrystal Biotech Inc (KRYS)
JNJ
Johnson & Johnson
$269.29
-0.10%
HEALTHCARE · Cap: $640.02B
KRYS
Krystal Biotech Inc
$350.88
+5.10%
HEALTHCARE · Cap: $9.88B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 22132% more annual revenue ($97.93B vs $440.48M). KRYS leads profitability with a 54.8% profit margin vs 21.5%. JNJ trades at a lower P/E of 30.9x. KRYS earns a higher WallStSmart Score of 65/100 (C+).
JNJ
Buy59
out of 100
Grade: C
KRYS
Buy65
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Keeps 55 of every $100 in revenue as profit
Strong operational efficiency at 49.0%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.1% year-over-year
Earnings expanding 38.8% YoY
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : KRYS
The strongest argument for KRYS centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 54.8% and operating margin at 49.0%. Revenue growth of 24.1% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : KRYS
The primary concerns for KRYS are P/E Ratio. A P/E of 41.9x leaves little room for execution misses.
Key Dynamics to Monitor
JNJ profiles as a mature stock while KRYS is a growth play — different risk/reward profiles.
KRYS carries more volatility with a beta of 0.54 — expect wider price swings.
KRYS is growing revenue faster at 24.1% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
KRYS scores higher overall (65/100 vs 59/100), backed by strong 54.8% margins and 24.1% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Krystal Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?